Alexion Pharmaceuticals (NASDAQ:ALXN) and BridgeBio Pharma’s (NASDAQ:BBIO) subsidiary Eidos Therapeutics (NASDAQ:EIDX) have announced an agreement that grants Alexion an exclusive license to develop and commercialize AG10 in Japan.
AG10 is a small molecule designed to treat the root cause of transthyretin amyloidosis (ATTR) – destabilized and misfolded transthyretin (TTR) protein – by binding and stabilizing TTR in the blood.
Eidos is currently evaluating AG10 in a Phase 3 study in the U.S. and Europe for ATTR cardiomyopathy and plans to begin a Phase 3 study in ATTR polyneuropathy in H2 2019.
Under the terms of the agreement, Eidos will receive an upfront payment of $25M and an equity investment of $25M, with the potential for additional Japanese-based milestone- and royalty-dependent payments.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.